Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter.

Chapman, Gregory D.; Lim, Chang Su; Gammon, Roger S.; Culp, Stephen C.; Desper, J S; Bauman, Robert P.; Swain, Judith L.; Stack, Richard S.

doi:10.1161/01.res.71.1.27

Cited by 110 publications

(37 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For targeting and diffuse delivery of genes into all layers of the myocardium, the selective infusion of genes through the coronary artery seems also to be superior to direct injection into the myocardium. [16][17][18] For coronary infusion of the vectors, either the use of a coronary catheter while the heart is beating or a surgical approach during cardioplegic arrest appears to be most suitable for clinical application. Barr and his associates 6 improved the efficiency of gene transfer into the myocardium by intracoronary gene transfection with adenovirus.…”

Section: Discussionmentioning

confidence: 99%

Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery

Sawa

Kaneda

et al. 1998

Gene Ther

View full text Add to dashboard Cite

Several of the current techniques for transfer of both olidetected in the nuclei of more than 70% of the myocytes gonucleotide and plasmid DNA into the myocardium are and endothelial cells both in the epicardium and endocarimpaired by low efficiency and toxicity. To improve gene dium. ␤-Gal was expressed in the cytosol of more than transfer techniques, especially into the whole heart, a gene 50% of the myocytes. ␤-Gal expression was demonstrated transfer method involving liposome in conjunction with a by Western blotting analysis at day 3 after transfection and viral envelope (HVJ-liposome) was essayed as an alternacontinued for at least 14 days. No significant histological tive. FITC-labeled oligonucleotide (F-ODN) and the cDNA damage of the myocardium or leakage of CPK were of ␤-galactosidase (␤-gal) were introduced into the myocardetected in the rats transfected by the HVJ-liposome dium by coronary infusion of HVJ-liposome during cardiomethod. These results clearly demonstrate that the hearts plegic arrest of adult Sprague-Dawley rat hearts. Then, were efficiently transfected both by oligonucleotide and transfected heart was ectopically transplanted into another plasmid DNA as a result of coronary infusion of HVJ-liporat abdomen of the same strain to maintain the transfected some during cardioplegic arrest. This thus appears to be heart long enough to allow for protein synthesis. After 3 an efficient method for gene transfer into the whole heart, days of transfection, transfected heart was excised and the providing a new tool for research and therapy for heart efficiency of gene transfection was evaluated. FITC was diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery

Sawa

Kaneda

et al. 1998

Gene Ther

View full text Add to dashboard Cite

show abstract

“…Several early studies of direct in vivo vascular gene delivery used plasmid DNA 1,[53][54][55] in complex with liposome-based carriers. Cationic liposomes interact with negatively charged plasmid DNA to form complexes able to fuse with cell membranes, releasing plasmid DNA into the cytoplasm.…”

Section: Plasmid-based Gene Transfermentioning

confidence: 99%

Gene Therapy for Restenosis

Baek

March

1998

Circulation Research

View full text Add to dashboard Cite

—Intensive work over the past decade has been directed to the study of vascular gene transfer as an approach to the unresolved problem of restenosis. This effort has resulted in a significant foundation of knowledge relative to the activities of potentially therapeutic gene products as well as the capabilities and limitations of vector systems and mechanical delivery modalities available for effecting the vascular expression of these gene products. In several instances, significant progress has been made by experiments highlighting unexpected difficulties and the need for more comprehensive understanding. It is thus now possible to clearly define and address specific challenges that must be overcome in order to make feasible progress from the preclinical to the clinical arena. The key challenges at present appear to include the evolution of clinically practical delivery methods that meet the kinetic requirements of achieving efficient gene transduction and the availability of vectors that maximize efficiency while minimizing undesirable host responses. Emerging data suggest that approaches to solving each of these issues may have recently been developed. Basic research evaluating these new delivery mechanisms and molecular vectors is essential to establish their true potential for use in the clinical arena.

show abstract

“…In a few studies, the transgene, inserted into the adenoviral genome, has been successfully delivered to the arterial wall using a percutaneous approach similar to the procedure used to perform coronary angioplasty (4,5,7,9,10). Despite the variation in catheter designs used, the resulting transfection efficiencies have been typically higher than those achieved with retroviral vectors (11,12) plasmid DNA/liposome complexes (11,13,14), or plasmid DNA alone (15,16). It is unclear, however, whether these results, obtained in normal or endothelium-denuded arteries, can be extended to more extensively diseased arteries (17).…”

Section: Introductionmentioning

confidence: 99%

Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit.

Feldman¹,

Steg²,

Zheng³

et al. 1995

J. Clin. Invest.

View full text Add to dashboard Cite

Recombinant adenoviruses are the most efficient vectors with which to perform arterial gene transfer. Previous in vivo studies of adenovirus-mediated arterial transfection, however, have been performed using normal or endothelium-denuded arteries. It is unclear whether these results can be extended to atherosclerotic arteries. Accordingly, this study was designed to (a) assess the feasibility of adenovirusmediated gene transfer to atherosclerotic lesions, and (b) compare the transfection efficiency, anatomic distribution of transfected cells, and duration of transgene expression achieved in normal versus atherosclerotic arteries. A recombinant adenovirus including a nuclear-targeted (-galactosidase gene was percutaneously delivered to the iliac artery of normal (n = 25) and atherosclerotic (n = 25) rabbits. Transgene expression, assessed by morphometric as well as chemiluminescent analyses, was documented in all normal and atherosclerotic arteries between 3 and 14 d after gene transfer, but was undetectable at later time points. Transfected cells were identified as smooth muscle cells located in the media of normal arteries, and in the neointima and the vasa-vasora of atherosclerotic arteries. Two percent of medial cells, but only 0.2% of medial and neointimal cells expressed the transgene in normal and atherosclerotic arteries, respectively (P = 0.0001). Similarly, nuclear ,B-galactosidase activity was higher in normal than in atherosclerotic arteries (3.2 vs. 0.8 mU/mg protein, P = 0.02). These findings indicate that atherosclerosis reduces the transfection efficiency which can be achieved with adenoviral vectors, and thus constitutes a potential limitation to adenovirus-based, arterial gene therapy. (J. Clin. Invest. 1995. 95:2662-2671

show abstract

Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter.

Cited by 110 publications

References 33 publications

Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery

Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery

Gene Therapy for Restenosis

Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit.

Contact Info

Product

Resources

About